Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
SNGX logo SNGX
Upturn stock ratingUpturn stock rating
SNGX logo

Soligenix Inc (SNGX)

Upturn stock ratingUpturn stock rating
$2.94
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/14/2025: SNGX (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

1 Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

1 Year Target Price $35

1 Year Target Price $35

Analysts Price Target For last 52 week
$35 Target price
52w Low $1.09
Current$2.94
52w High $5.4

Analysis of Past Performance

Type Stock
Historic Profit -31.55%
Avg. Invested days 35
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/14/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 9.60M USD
Price to earnings Ratio -
1Y Target Price 35
Price to earnings Ratio -
1Y Target Price 35
Volume (30-day avg) 1
Beta 1.96
52 Weeks Range 1.09 - 5.40
Updated Date 08/15/2025
52 Weeks Range 1.09 - 5.40
Updated Date 08/15/2025
Dividends yield (FY) -
Basic EPS (TTM) -3.13

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -454073.83%

Management Effectiveness

Return on Assets (TTM) -84.11%
Return on Equity (TTM) -437.73%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 2379131
Price to Sales(TTM) 4097.86
Enterprise Value 2379131
Price to Sales(TTM) 4097.86
Enterprise Value to Revenue 1.87
Enterprise Value to EBITDA -0.12
Shares Outstanding 3264350
Shares Floating 3263693
Shares Outstanding 3264350
Shares Floating 3263693
Percent Insiders 0.02
Percent Institutions 5.02

ai summary icon Upturn AI SWOT

Soligenix Inc

stock logo

Company Overview

overview logo History and Background

Soligenix, Inc. was founded in 2003. The company focuses on developing and commercializing products to treat rare diseases where there is an unmet need. It has evolved from focusing on biodefense vaccines to including a broader pipeline of rare disease therapeutics.

business area logo Core Business Areas

  • Dermatology: Soligenix is developing HyBryteu2122 (SGX301 or synthetic hypericin) as a potential first-in-class treatment for cutaneous T-cell lymphoma (CTCL).
  • Gastroenterology: SGX302 (oral beclomethasone 17,21-dipropionate (BDP) is in development for the prevention of acute gastrointestinal graft-versus-host disease (GI GVHD) after allogeneic hematopoietic stem cell transplantation.
  • Vaccines/Biodefense: Soligenix is also developing vaccines and therapeutics for biodefense purposes, including RiVaxu00ae, a ricin toxin vaccine and CiVaxu2122, a heat stable COVID-19 vaccine.

leadership logo Leadership and Structure

Christopher J. Schaber, PhD is the President and CEO. The company has a typical corporate structure with a board of directors and executive management team overseeing various departments such as R&D, clinical development, and commercial operations.

Top Products and Market Share

overview logo Key Offerings

  • HyBryte (SGX301): HyBryte is a potential first-in-class treatment for cutaneous T-cell lymphoma (CTCL). Market share is currently N/A as the product is still under regulatory review for marketing approval. Competitors: Valchlor (mechlorethamine), Bexarotene.
  • SGX302 (oral BDP): SGX302 (oral beclomethasone 17,21-dipropionate (BDP) is in development for the prevention of acute gastrointestinal graft-versus-host disease (GI GVHD) after allogeneic hematopoietic stem cell transplantation. Market share is currently N/A as the product is still under development. Competitors: Corticosteroids, immunosuppressants.
  • RiVax: RiVax is a ricin toxin vaccine candidate for biodefense purposes. Market share is currently N/A as the product is still under development. Competitors: Emergent BioSolutions.
  • CiVax: CiVax is a heat stable COVID-19 vaccine. Market share is currently N/A as the product is still under development. Competitors: Pfizer, Moderna, Novavax.

Market Dynamics

industry overview logo Industry Overview

The biopharmaceutical industry is characterized by high R&D costs, lengthy regulatory approval processes, and intense competition. The rare disease market, in particular, is attracting increasing attention due to favorable regulatory incentives and pricing power.

Positioning

Soligenix is positioned as a specialty pharmaceutical company focused on developing and commercializing niche products in rare diseases. Its competitive advantage lies in its proprietary technologies and targeted approach to addressing unmet medical needs.

Total Addressable Market (TAM)

The TAM for CTCL, where HyBryte is being developed, is estimated to be significant (hundreds of millions of USD). The TAM for GI GVHD is also substantial. Soligenix is positioned to capture a share of these markets upon successful commercialization.

Upturn SWOT Analysis

Strengths

  • Proprietary technologies
  • Focus on rare diseases with unmet needs
  • Experienced management team
  • Diversified product pipeline

Weaknesses

  • Limited financial resources
  • Dependence on successful clinical trials and regulatory approvals
  • Lack of commercial infrastructure
  • History of operating losses

Opportunities

  • Fast-track regulatory pathways for rare diseases
  • Partnerships and collaborations with larger pharmaceutical companies
  • Expansion into new therapeutic areas
  • Potential for orphan drug designation

Threats

  • Clinical trial failures
  • Regulatory setbacks
  • Competition from established pharmaceutical companies
  • Generic erosion of marketed products

Competitors and Market Share

competitor logo Key Competitors

  • VRX
  • MRK
  • BMY
  • TEVA

Competitive Landscape

Soligenix faces significant competition from established pharmaceutical companies with greater financial resources and commercial infrastructure. Its success depends on its ability to differentiate its products and secure regulatory approvals.

Growth Trajectory and Initiatives

Historical Growth: Historical growth has been limited due to the developmental stage of the company's product pipeline.

Future Projections: Future growth is dependent on the successful commercialization of HyBryte and other pipeline products. Analyst estimates vary widely.

Recent Initiatives: Recent initiatives include advancing HyBryte through regulatory review and progressing other pipeline programs through clinical development.

Summary

Soligenix is a development-stage biopharmaceutical company focused on rare diseases. Its strengths lie in its niche focus and pipeline, but its weaknesses include limited resources and dependence on clinical success. The company needs to secure partnerships and achieve regulatory approvals to unlock its potential, while keeping an eye on maintaining sufficient cash flow to weather the developmental milestones.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • SEC Filings
  • Company Website
  • Analyst Reports
  • Third-Party Financial Data Providers

Disclaimers:

This analysis is for informational purposes only and does not constitute investment advice. Market share estimates are based on available data and may not be precise. Financial data is subject to change.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Soligenix Inc

Exchange NASDAQ
Headquaters Princeton, NJ, United States
IPO Launch date 1987-06-15
Chairman of the Board of Directors, CEO & President Dr. Christopher J. Schaber Ph.D.
Sector Healthcare
Industry Biotechnology
Full time employees 14
Full time employees 14

Soligenix, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of products to treat rare diseases in the United States. It operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a photodynamic therapy, which has completed Phase 3 clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator (IDR) technology that is in Phase 3 clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX945, an IDR technology that is in Phase 2a study to treat aphthous ulcers in Behçet's disease; and SGX302, an IDR technology, which is in Phase 2a study for the treatment of mild-to-moderate psoriasis. Its Public Health Solutions segment engages in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase 1a, 1b, and 1c clinical trials; SGX943, a therapeutic candidate in preclinical studies for the treatment of antibiotic-resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; CiVax, a vaccine candidate for the prevention of COVID-19; and vaccine programs that target filoviruses, such as Marburg and Ebola. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in September 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.